Targeting ribonucleotide reductase for cancer therapy

Jimin Shao, Xiyong Liu, Lijun Zhu, Yun Yen

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Introduction: Ribonucleotide reductase (RR) is a unique enzyme, because it is responsible for reducing ribonucleotides to their corresponding deoxyribonucleotides, which are the building blocks required for DNA replication and repair. Dysregulated RR activity is associated with genomic instability, malignant transformation and cancer development. The use of RR inhibitors, either as a single agent or combined with other therapies, has proven to be a promising approach for treating solid tumors and hematological malignancies. Areas covered: This review covers recent publications in the area of RR, which include: i) the structure, function and regulation of RR; ii) the roles of RR in cancer development; iii) the classification, mechanisms and clinical application of RR inhibitors for cancer therapy and iv) strategies for developing novel RR inhibitors in the future. Expert opinion: Exploring the possible nonenzymatic roles of RR subunit proteins in carcinogenesis may lead to new rationales for developing novel anticancer drugs. Updated information about the structure and holoenzyme models of RR will help in identifying potential sites in the protein that could be targets for novel RR inhibitors. Determining RR activity and subunit levels in clinical samples will provide a rational platform for developing personalized cancer therapies that use RR inhibitors.

Original languageEnglish
Pages (from-to)1423-1437
Number of pages15
JournalExpert Opinion on Therapeutic Targets
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 1 2013
Externally publishedYes

Fingerprint

Ribonucleotide Reductases
Neoplasms
Therapeutics
Deoxyribonucleotides
Ribonucleotides
Holoenzymes
Genomic Instability
Protein Subunits
Expert Testimony
Hematologic Neoplasms
DNA Replication
DNA Repair
Tumors

Keywords

  • Anticancer therapy
  • Inhibitors
  • Mechanism of action
  • Ribonucleotide reductase
  • Structure and function

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Targeting ribonucleotide reductase for cancer therapy. / Shao, Jimin; Liu, Xiyong; Zhu, Lijun; Yen, Yun.

In: Expert Opinion on Therapeutic Targets, Vol. 17, No. 12, 01.12.2013, p. 1423-1437.

Research output: Contribution to journalReview article

Shao, Jimin ; Liu, Xiyong ; Zhu, Lijun ; Yen, Yun. / Targeting ribonucleotide reductase for cancer therapy. In: Expert Opinion on Therapeutic Targets. 2013 ; Vol. 17, No. 12. pp. 1423-1437.
@article{f62fc2d7953949f09acd1bcbbffe450a,
title = "Targeting ribonucleotide reductase for cancer therapy",
abstract = "Introduction: Ribonucleotide reductase (RR) is a unique enzyme, because it is responsible for reducing ribonucleotides to their corresponding deoxyribonucleotides, which are the building blocks required for DNA replication and repair. Dysregulated RR activity is associated with genomic instability, malignant transformation and cancer development. The use of RR inhibitors, either as a single agent or combined with other therapies, has proven to be a promising approach for treating solid tumors and hematological malignancies. Areas covered: This review covers recent publications in the area of RR, which include: i) the structure, function and regulation of RR; ii) the roles of RR in cancer development; iii) the classification, mechanisms and clinical application of RR inhibitors for cancer therapy and iv) strategies for developing novel RR inhibitors in the future. Expert opinion: Exploring the possible nonenzymatic roles of RR subunit proteins in carcinogenesis may lead to new rationales for developing novel anticancer drugs. Updated information about the structure and holoenzyme models of RR will help in identifying potential sites in the protein that could be targets for novel RR inhibitors. Determining RR activity and subunit levels in clinical samples will provide a rational platform for developing personalized cancer therapies that use RR inhibitors.",
keywords = "Anticancer therapy, Inhibitors, Mechanism of action, Ribonucleotide reductase, Structure and function",
author = "Jimin Shao and Xiyong Liu and Lijun Zhu and Yun Yen",
year = "2013",
month = "12",
day = "1",
doi = "10.1517/14728222.2013.840293",
language = "English",
volume = "17",
pages = "1423--1437",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Targeting ribonucleotide reductase for cancer therapy

AU - Shao, Jimin

AU - Liu, Xiyong

AU - Zhu, Lijun

AU - Yen, Yun

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Introduction: Ribonucleotide reductase (RR) is a unique enzyme, because it is responsible for reducing ribonucleotides to their corresponding deoxyribonucleotides, which are the building blocks required for DNA replication and repair. Dysregulated RR activity is associated with genomic instability, malignant transformation and cancer development. The use of RR inhibitors, either as a single agent or combined with other therapies, has proven to be a promising approach for treating solid tumors and hematological malignancies. Areas covered: This review covers recent publications in the area of RR, which include: i) the structure, function and regulation of RR; ii) the roles of RR in cancer development; iii) the classification, mechanisms and clinical application of RR inhibitors for cancer therapy and iv) strategies for developing novel RR inhibitors in the future. Expert opinion: Exploring the possible nonenzymatic roles of RR subunit proteins in carcinogenesis may lead to new rationales for developing novel anticancer drugs. Updated information about the structure and holoenzyme models of RR will help in identifying potential sites in the protein that could be targets for novel RR inhibitors. Determining RR activity and subunit levels in clinical samples will provide a rational platform for developing personalized cancer therapies that use RR inhibitors.

AB - Introduction: Ribonucleotide reductase (RR) is a unique enzyme, because it is responsible for reducing ribonucleotides to their corresponding deoxyribonucleotides, which are the building blocks required for DNA replication and repair. Dysregulated RR activity is associated with genomic instability, malignant transformation and cancer development. The use of RR inhibitors, either as a single agent or combined with other therapies, has proven to be a promising approach for treating solid tumors and hematological malignancies. Areas covered: This review covers recent publications in the area of RR, which include: i) the structure, function and regulation of RR; ii) the roles of RR in cancer development; iii) the classification, mechanisms and clinical application of RR inhibitors for cancer therapy and iv) strategies for developing novel RR inhibitors in the future. Expert opinion: Exploring the possible nonenzymatic roles of RR subunit proteins in carcinogenesis may lead to new rationales for developing novel anticancer drugs. Updated information about the structure and holoenzyme models of RR will help in identifying potential sites in the protein that could be targets for novel RR inhibitors. Determining RR activity and subunit levels in clinical samples will provide a rational platform for developing personalized cancer therapies that use RR inhibitors.

KW - Anticancer therapy

KW - Inhibitors

KW - Mechanism of action

KW - Ribonucleotide reductase

KW - Structure and function

UR - http://www.scopus.com/inward/record.url?scp=84887953940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887953940&partnerID=8YFLogxK

U2 - 10.1517/14728222.2013.840293

DO - 10.1517/14728222.2013.840293

M3 - Review article

VL - 17

SP - 1423

EP - 1437

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 12

ER -